ストックスクリーナーアプリを入手
1.86
4.49%
0.08
前日終値:
$1.78
開ける：
$1.77
24時間の取引高:
182.85K
Relative Volume:
0.48
時価総額：
$65.88M
収益：
-
当期純損益:
$-57.33M
株価収益率:
-1.287
EPS:
-1.4452
ネットキャッシュフロー:
$-42.44M
1週間 パフォーマンス:
+4.79%
1か月 パフォーマンス:
+223.48%
6か月 パフォーマンス:
+151.15%
1年 パフォーマンス:
-50.40%
1日の値動き範囲:
$1.77
$1.95
1週間の範囲:
$1.64
$2.05
52週間の値動き範囲:
$0.255
$4.9902
Skye Bioscience Inc Stock (SKYE) Company Profile
名前
Skye Bioscience Inc
セクター
電話
(858) 410-0266
住所
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Compare SKYE vs PSNYW, GOODO, SHMD, DWLD, QQQE
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
5.00 | 394.14M | 2.07B | -1.42B | -1.37B | -0.6765 |
GOODO
Gladstone Commercial Corporation
|
20.92 | 372.90M | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
3.15 | 315.90M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
47.39 | 0 | 0 | 0 | 0 | 0.00 |
QQQE
Direxion NASDAQ-100 Equal Weigh
|
120.75 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-06 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-06 | ダウングレード | Craig Hallum | Buy → Hold |
| 2025-08-15 | 開始されました | Evercore ISI | Outperform |
| 2025-02-28 | 開始されました | William Blair | Outperform |
| 2024-09-30 | 開始されました | Scotiabank | Sector Outperform |
| 2024-09-10 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-07-09 | 開始されました | Craig Hallum | Buy |
| 2024-05-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-04-12 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Skye Bioscience Inc (SKYE) 最新ニュース
Skye Bioscience director Andrew Schwab sells $140,313 in stock By Investing.com - Investing.com India
Skye Bioscience director Andrew Schwab sells $140,313 in stock - Investing.com
5am Partners VII, LLC sells $140,313 of Skye Bioscience stock - Investing.com
Skye Bioscience (SKYE) insider funds sell 375,840 shares at $0.32–$0.41 - Stock Titan
Skye Bioscience (SKYE) 5AM funds sell at penny-level prices - Stock Titan
Skye Bioscience, Inc. Common Stock (NASDAQ: SKYE) Share Price, SKYE Stock News, SKYE Share Price & Updates - Kalkine
Form 8K Skye Bioscience Inc For: 19 August By Investing.com - Investing.com South Africa
Skye Bioscience flags Nasdaq noncompliance after stockholders’ equity falls to ($497,307) - Bitget
SKYE BIOSCIENCE INC(SKYE) Stock Options Chain | Quotes & News - Moomoo
Skye Bioscience Faces Nasdaq Compliance and Delisting Risk - TipRanks
Skye Bioscience receives Nasdaq notice for non-compliance with equity listing rule - Investing.com
Skye Bioscience Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Skye Bioscience (NASDAQ: SKYE) faces deadline to fix negative equity - Stock Titan
Skye Bioscience (SKYE) holder sells shares, funds Redx merger - Stock Titan
$SKYE BIOSCIENCE INC (SKYE.US)$ sure feels like it 😒 - Moomoo
Skye Bioscience Inc (SKYE) (Q2 2026) Earnings Call Highlights: S - GuruFocus
Skye Bioscience, Inc. (SKYE) Skye Bioscience, Inc.M&A CallSlideshow (NASDAQ:SKYE) 2026-08-16 - Seeking Alpha
Skye (SKYE) Drops -7.21% — Key Support at $0.47 2026-08-15Sign of Weakness - vinanet.vn
Skye drops obesity program, combines with Redx to form Fibrx - AllSci
Redx tries again at reverse merger, with Skye this time, as alternative route gains steam - Endpoints News
Skye Bioscience Q2 Loss Narrows Sharply on Lower R&D Spending - Minichart
SKYE: Merger creates Fibrx, a well-funded fibrosis company advancing RXC008 for Crohn's disease - TradingView
Skye Bioscience to Be Acquired by Redx Pharma in $264.5M Nasdaq-Listed Merger - Minichart
SKYE: Merger creates a well-funded fibrosis company advancing RXC008 for Crohn's disease, with phase II data due 2029 - TradingView
Form 8K Skye Bioscience Inc For: 14 August By Investing.com - Investing.com Nigeria
Skye Bioscience to acquire Redx Pharma in $125M deal By Investing.com - Investing.com Nigeria
Skye Bioscience to acquire Redx Pharma in $125M deal - Investing.com
Skye Bioscience to Acquire Redx; Secures $67.9M Financing and $22M Equity Line - TradingView
Skye Bioscience, Inc. 2026: Revenue $178.2K, EPS ($0.27) — 10-Q Summary - TradingView
Skye Bioscience (NASDAQ: SKYE) exits obesity trial, pursues Redx merger and $100M+ funding - Stock Titan
Skye Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings - marketscreener.com
Skye Bioscience (SKYE) Climbs 1.66% to $0.55: Consolidation Nears a Critical JunctureRating Change - Vinanet
SKYE Q1 2026 Earnings: Narrow EPS Miss Reflects Continued Clinical-Stage InvestmentEstimate Revision Count - vinanet.vn
SKYE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Skye Bioscience (SKYE) Jumps 10% as Shares Approach Key $0.55 ResistanceRounding Bottom - Vinanet
Skye Bioscience Inc (SKYE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Skye Bioscience Inc (SKYE) Stock News Today - TradingKey
SKYE Stockholders Have Opportunity to Lead Skye Bioscience, Inc - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, In - The National Law Review
SKYE Q2'26 Earnings: EPS estimate is (0.24) USD - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Skye Bioscien - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Skye Bioscience Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
Skye Bioscience2026 Funding Rounds & List of Investors - Tracxn
Skye Bioscience, Inc. Revenue Breakdown – NASDAQ:SKYE - TradingView
Skye Bioscience Inc. (SKYE) Q1 2026 Earnings: Clinical-Stage Losses Slightly Wider Than ConsensusEPS Surprise History - dars.gov.et
Skye Bioscience Inc (SKYE) Cash Flow - TradingKey
Skye Bioscience Inc (SKYE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
SKYE|Skye Bioscience Inc|Price:0.625|Chg%:-0.027 - TradingKey
Skye Bioscience Inc (SKYE) 財務データ
収益
当期純利益
現金流量
EPS
Skye Bioscience Inc (SKYE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Schwab Andrew J. | Director |
Aug 19 '26 |
Sale |
0.35 |
68,140 |
23,849 |
55,254 |
| Schwab Andrew J. | Director |
Aug 20 '26 |
Sale |
0.32 |
7,700 |
2,464 |
55,208 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 18 '26 |
Sale |
0.38 |
300,000 |
114,000 |
55,663 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 19 '26 |
Sale |
0.35 |
68,140 |
23,849 |
55,254 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 20 '26 |
Sale |
0.32 |
7,700 |
2,464 |
55,208 |
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):